ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 946

Improvements in Disease Activity and Quality of Life for up to 64 Weeks in Patients with Behçet’s Syndrome: Results from a Phase III Study

Gulen Hatemi1, Alfred Mahr 2, Mitsuhiro Takeno 3, Doyoung Kim 4, Melike Melikoglu 5, Sue Cheng 6, Shannon McCue 7, Maria Paris 6, Mindy Chen 8 and Yusuf Yazici 9, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Behcet's Disease Research Center, Istanbul, Turkey, Istanbul, Turkey, 2Hospital Saint-Louis, University Paris Diderot, Paris, France, 3Nippon Medical School, Tokyo, Japan, 4Yonsei University College of Medicine and Severance Hospital, Seoul, Republic of Korea, 5Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul University – Cerrahpasa, Behçet’s Disease Research Center, Istanbul, Turkey, Istanbul, Turkey, 6Celgene Corporation, Summit, 7Celgene Corporation, Summit, NJ, 8Celgene Corporation, Berkeley Heights, NJ, 9New York University School of Medicine, New York

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Behcet's syndrome, clinical trials, Disease Activity, quality of life and PRO

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: 3S112: Vasculitis – Non-ANCA-Associated & Related Disorders I: Miscellaneous Disorders (945–950)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Behçet’s syndrome is a chronic, multi-system inflammatory disorder characterized by painful, recurrent oral ulcers (OU) that can impair quality of life (QoL). Apremilast (APR), an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in the treatment of OU of Behçet’s syndrome in a phase III, multicenter, randomized, double-blind, placebo (PBO)-controlled study (RELIEF). We report short- and long-term results from RELIEF for the efficacy of APR treatment on QoL and physical function for up to 64 weeks.

Methods: A total of 207 patients were randomized (1:1) to APR 30 mg twice daily (APR 30 BID) or PBO twice daily for a 12-week PBO-controlled phase, followed by a 52-week active treatment extension. Eligible patients were ≥18 years old, had active Behçet’s syndrome, with ≥3 OU at randomization or ≥2 OU at screening and randomization and without active major organ involvement. The primary efficacy endpoint was area under the curve for the number of OU over 12 weeks (AUCWk0-12). Clinical improvement of OU was evaluated by assessments of OU pain (100 mm visual analogue scale) and measures of disease activity and QoL. Disease activity measures included the Behçet’s Syndrome Activity Score (BSAS) and Behçet’s Disease Current Activity Index Form (BDCAF; including 3 components: Behçet’s Disease Current Activity Index, Patient’s Perception of Disease Activity, Clinician’s Overall Perception of Disease Activity). QoL assessments included the Behçet’s Disease QoL (BDQoL) score and the 36-item Short-Form Health Survey version 2 (SF-36v2), consisting of the Physical and Mental Component Summary (PCS and MCS) scores and Physical Functioning domain (PF) score. An analysis of covariance model was used to analyze the primary endpoint and change from baseline in BDQoL score and SF-36v2 PCS, MCS and PF scores at Week 12. Data at Week 64 are as observed.

Results: The primary efficacy endpoint of AUCWk0-12 for the number of OU was significantly lower in APR 30 BID vs PBO patients (P< 0.0001); improvement in the number of OU and OU pain was sustained in patients continuing APR 30 BID treatment for up to 64 weeks and emerged in patients switched from PBO to APR 30 BID for Weeks 12 to 64. Significant improvements were observed with APR 30 BID vs PBO in mean change from baseline at Week 12 in BSAS (P< 0.0001), BDCAF components (P≤0.0335), and BDQoL score (P=0.0003). The improvements in BSAS, BDCAF, and BDQoL outcomes were maintained in patients continuing APR 30 BID treatment for up to 64 weeks, and comparable effects were observed at Week 64 among patients who switched from PBO to APR 30 BID. Significant improvements were also observed in mean change from baseline at Week 12 in SF-36v2 PCS (P=0.0204), MCS (P< 0.0001), and PF (P=0.0060) scores in APR 30 BID vs PBO patients. These effects in SF-36v2 scores were also maintained at Week 64 among patients initially randomized to APR 30 BID, and the improvements were generally similar among patients who switched from PBO to APR 30 BID (Table).

Conclusion: Patients with active Behçet’s syndrome treated with APR 30 BID vs PBO experienced significant reductions in OU and clinically meaningful improvements at Week 12 in disease activity and QoL. Improvements were sustained at Week 64 in patients continuing APR treatment.


Disclosure: G. Hatemi, Abbvie, Mustafa Nevzet, UCB, 8, Bayer, Eli Lilly, 5, BMS, Celgene Corporation, Silk Road Therapeutics, 2, Silk Road Therapeutics, 2; A. Mahr, Celgene, 8, Chugai Pharma France, 8, Roche, 8, Roche, Chugai, 8; M. Takeno, Celgene Corporation, 5, Mitsubishi-Tanabe, 8; D. Kim, None; M. Melikoglu, None; S. Cheng, Celgene Corporation, 3; S. McCue, Celgene Corporation, 3; M. Paris, Celgene Corporation, 3; M. Chen, Celgene Corporation, 3; Y. Yazici, BMS, Celgene Corporation, Genentech, and Sanofi, 5, BMS, Celgene Corporation, Genetech, Sanofi, 5.

To cite this abstract in AMA style:

Hatemi G, Mahr A, Takeno M, Kim D, Melikoglu M, Cheng S, McCue S, Paris M, Chen M, Yazici Y. Improvements in Disease Activity and Quality of Life for up to 64 Weeks in Patients with Behçet’s Syndrome: Results from a Phase III Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/improvements-in-disease-activity-and-quality-of-life-for-up-to-64-weeks-in-patients-with-behcets-syndrome-results-from-a-phase-iii-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improvements-in-disease-activity-and-quality-of-life-for-up-to-64-weeks-in-patients-with-behcets-syndrome-results-from-a-phase-iii-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology